Expert Perspectives on the Evolving Treatment Landscape of Multiple Myeloma

home / peer-exchange / expert-perspectives-on-the-evolving-treatment-landscape-of-multiple-myeloma

A panel of key opinion leaders gather for a discussion on recent data updates in the treatment of multiple myeloma that were recently presented at ASH 2022, and how they impact clinical practice and treatment recommendations.

EP. 1: Data Updates in the Frontline Treatment of Patients With Transplant-Eligible Multiple Myeloma

By Sagar Lonial, MD
Amrita Krishnan, MD

December 22nd 2022

Sagar Lonial, MD, introduces the expert panel and starts a conversation on data updates in the treatment of transplant-eligible multiple myeloma.

EP. 2: Considerations for Frontline Treatment in Transplant-Ineligible Multiple Myeloma

By Sagar Lonial, MD
Amrita Krishnan, MD

December 22nd 2022

Hana Safah, MD, explains the common treatment approaches for patients with transplant-ineligible multiple myeloma.

EP. 3: Defining Frailty in Multiple Myeloma for Optimal Treatment

By Sagar Lonial, MD
Amrita Krishnan, MD

January 23rd 2023

Amrita Krishnan, MD, and Hana Safah, MD, discuss how to measure frailty in patient with multiple myeloma.

EP. 4: Approaches to Treatment Duration in Newly-Diagnosed Multiple Myeloma

By Sagar Lonial, MD
Amrita Krishnan, MD

January 23rd 2023

Noopur Raje, MD, details the data on treatment duration in older patients with multiple myeloma and transplant-eligible patients.

EP. 5: Relapse in Multiple Myeloma: Biochemical and Chemical

By Sagar Lonial, MD
Amrita Krishnan, MD

January 30th 2023

Dr Amrita Krishnan explains the difference between biochemical and clinical relapse in multiple myeloma.

EP. 6: Data Updates in the Treatment of Relapsed Multiple Myeloma

By Sagar Lonial, MD
Amrita Krishnan, MD

January 30th 2023

Drs Hana Safah and Krina Patel share data from key clinical trials investigating the treatment of relapsed multiple myeloma.

EP. 7: Strategies for Treatment of Multiple Myeloma at Late Relapse

By Sagar Lonial, MD
Amrita Krishnan, MD

February 6th 2023

The panel debates the options for treatment of late relapsed multiple myeloma.

EP. 8: Quadruplet Combination Therapies in Relapsed Multiple Myeloma

By Sagar Lonial, MD
Amrita Krishnan, MD

February 6th 2023

Hana Safa, MD, shares data on quadruplet therapies in the treatment of relapsed multiple myeloma.

EP. 9: Considerations for Treatment Decision-Making in Early-Relapse Multiple Myeloma

By Sagar Lonial, MD
Amrita Krishnan, MD

February 13th 2023

Noopur Raje, MD, explains the treatment decision-making process for early relapse multiple myeloma.

EP. 10: CD38 Monoclonal Antibodies for Early Relapsed Multiple Myeloma and the Risk of COVID Infection

By Sagar Lonial, MD
Amrita Krishnan, MD

February 13th 2023

The panel discusses the strategies for reducing or preventing COVID infection in patients being treated for early relapse multiple myeloma with CD38 monoclonal antibodies.

$BCMA-Targeting Bispecifics in Relapsed/Refractory Multiple Myeloma$

EP. 11: BCMA-Targeting Bispecifics in Relapsed/Refractory Multiple Myeloma

By Sagar Lonial, MD
Amrita Krishnan, MD

February 20th 2023

Hana Safah, MD, and Noopur Raje, MD, discuss data on BCMA-targeting bispecifics teclistamab and elrantamab for treatment of relapsed/refractory multiple myeloma.

EP. 12: Retreatment with a BCMA-Targeting Bispecific for R/R MM

By Sagar Lonial, MD
Amrita Krishnan, MD

February 20th 2023

Amrita Krishnan, MD, details how she approaches retreating a patient with R/R MM with a BCMA-targeting bispecific agent.

EP. 13: Data Updates on Immunotherapy Combinations in Multiple Myeloma

By Sagar Lonial, MD
Amrita Krishnan, MD

February 27th 2023

Krina Patel, MD, reviews recent data from the MAJESTIC studies on immunotherapy combination treatments in R/R MM.

EP. 14: Targets in Multiple Myeloma: GPRC5D

By Sagar Lonial, MD
Amrita Krishnan, MD

February 27th 2023

Amrita Krishnan, MD, discusses targeting GPRC5D in multiple myeloma, and where it fits in the treatment sequence.